Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib

Research output: Contribution to journalReview article


Over the past 10 years, sorafenib has been the only systemic agent approved for the treatment of patients with unresectable hepatocellular carcinoma. Recently, lenvatinib was demonstrated noninferior to sorafenib, and regorafenib and ramucirumab were demonstrated superior to placebo in patients progressing on sorafenib and in patients with elevated α-fetoprotein-failing sorafenib, respectively. Phase I-II trials of immune checkpoint inhibitors reported promising efficacy signals. Recently, the randomized, placebo-controlled, Phase III CELESTIAL trial demonstrated statistically and clinically significant increase in overall survival from 8 months with placebo to 10.2 months with cabozantinib in patients failing sorafenib. Furthermore, the study showed a significant improvement in all the efficacy end points. Main adverse events were palmar-plantar erythrodysesthesia, hypertension, increased aspartate aminotransferase, fatigue and diarrhea.

Original languageEnglish
Pages (from-to)2449-2462
Number of pages14
JournalFuture oncology (London, England)
Issue number21
Publication statusPublished - Jul 2019


  • Anilides/chemistry
  • Animals
  • Antineoplastic Agents/chemistry
  • Carcinoma, Hepatocellular/drug therapy
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Drug Resistance, Neoplasm
  • Humans
  • Liver Neoplasms/drug therapy
  • Molecular Structure
  • Molecular Targeted Therapy
  • Neoplasm Staging
  • Neovascularization, Pathologic/drug therapy
  • Prognosis
  • Protein Kinase Inhibitors/chemistry
  • Pyridines/chemistry
  • Randomized Controlled Trials as Topic
  • Retreatment
  • Sorafenib/therapeutic use
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib'. Together they form a unique fingerprint.

  • Cite this